Skip to main content
Top
Published in: Thrombosis Journal 1/2023

Open Access 01-12-2023 | Hepatic Encephalopathy | Research

Development and external validation of prognostic scoring models for portal vein thrombosis: a multicenter retrospective study

Authors: Xuan Zhong, Shan Li, Jiali Hu, Jinlai Lu, Wei Wang, Miao Hu, Qinjuan Sun, Shuo Zhang, Xiaoqing Yang, Changqing Yang, Lan Zhong

Published in: Thrombosis Journal | Issue 1/2023

Login to get access

Abstract

Background

Portal vein thrombosis is a common complication of liver cirrhosis and hepatocellular carcinoma; however, few studies have reported its long-term clinical prognosis. This study aimed to establish and validate easy-to-use nomograms for predicting gastrointestinal bleeding, portal vein thrombosis resolution, and mortality of patients with portal vein thrombosis.

Methods

This multicenter retrospective cohort study included 425 patients with portal vein thrombosis who were divided into training (n = 334) and validation (n = 91) sets. Prediction models were developed using multivariate Cox regression analysis and evaluated using the consistency index and calibration plots.

Results

Predictors of gastrointestinal bleeding included a history of gastrointestinal bleeding, superior mesenteric vein thrombosis, red color sign observed during endoscopy, and hepatic encephalopathy. Meanwhile, predictors of resolution of portal vein thrombosis included a history of abdominal infection, C-reactive protein and hemoglobin levels, and intake of thrombolytics. Predictors of death included abdominal infection, abdominal surgery, aspartate aminotransferase level, hepatic encephalopathy, and ascites. All models had good discriminatory power and consistency. Anticoagulation therapy significantly increased the probability of thrombotic resolution without increasing the risk of bleeding or death.

Conclusions

We successfully developed and validated three prediction models that can aid in the early evaluation and treatment of portal vein thrombosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver Diseases Vascular disorders of the liver. Hepatology. 2009;49:1729–64.CrossRef DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver Diseases Vascular disorders of the liver. Hepatology. 2009;49:1729–64.CrossRef
2.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.CrossRef
3.
go back to reference Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis. 2020;2020(36):2667–74. Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis. 2020;2020(36):2667–74.
4.
go back to reference Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol. 2018;31:315–29. Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol. 2018;31:315–29.
5.
go back to reference Riva N, Poli D, Testa S, Rupoli S, et al. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thromb Haemost. 2015;13:1019–27.CrossRef Riva N, Poli D, Testa S, Rupoli S, et al. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thromb Haemost. 2015;13:1019–27.CrossRef
6.
go back to reference Ogren M, Bergqvist D, Bjorck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol: WJG. 2006;12:2115–9.CrossRef Ogren M, Bergqvist D, Bjorck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol: WJG. 2006;12:2115–9.CrossRef
7.
go back to reference Senzolo M, Sartori TM, Valeria R, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32:919–27.CrossRef Senzolo M, Sartori TM, Valeria R, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32:919–27.CrossRef
8.
go back to reference Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:210–8.CrossRef Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:210–8.CrossRef
9.
go back to reference Chung JW, Kim GH, Lee JH, Ok KS, Jang ES, et al. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol. 2014;20:384–91.CrossRef Chung JW, Kim GH, Lee JH, Ok KS, Jang ES, et al. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol. 2014;20:384–91.CrossRef
10.
go back to reference Blasi A. Coagulopathy in liver disease: lack of an assessment tool. World J Gastroenterol. 2015;21:10062–71.CrossRef Blasi A. Coagulopathy in liver disease: lack of an assessment tool. World J Gastroenterol. 2015;21:10062–71.CrossRef
11.
go back to reference Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology. 2016;63:1640–50.CrossRef Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology. 2016;63:1640–50.CrossRef
12.
go back to reference Xu W, Cheng Y, Tu B. Construction and validation of a nomogram for predicting the risk of portal vein thrombosis after splenectomy in patients with hepatitis B cirrhosis. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40:1265–72. Xu W, Cheng Y, Tu B. Construction and validation of a nomogram for predicting the risk of portal vein thrombosis after splenectomy in patients with hepatitis B cirrhosis. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40:1265–72.
13.
go back to reference Danila M, Sporea I, Popescu A, et al. Portal vein thrombosis in liver cirrhosis - the added value of contrast enhanced ultrasonography. Med Ultrason. 2016;18:218–33.CrossRef Danila M, Sporea I, Popescu A, et al. Portal vein thrombosis in liver cirrhosis - the added value of contrast enhanced ultrasonography. Med Ultrason. 2016;18:218–33.CrossRef
14.
go back to reference Maruyama H, Okugawa H, Takahashi M, Yokosuka O, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108:568–74.CrossRef Maruyama H, Okugawa H, Takahashi M, Yokosuka O, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108:568–74.CrossRef
15.
go back to reference Pettinari I, Vukotic R, Stefanescu H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114:258–66.CrossRef Pettinari I, Vukotic R, Stefanescu H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114:258–66.CrossRef
16.
go back to reference Turnes J, García-Pagán JC, González M, Aracil C, et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol. 2008;6:1412–7. Turnes J, García-Pagán JC, González M, Aracil C, et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol. 2008;6:1412–7.
17.
go back to reference Chen H, Turon F, Hernández-Gea V, Fuster J, Garcia-Criado A, et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liver Transplant. 2016;22:352–65.CrossRef Chen H, Turon F, Hernández-Gea V, Fuster J, Garcia-Criado A, et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liver Transplant. 2016;22:352–65.CrossRef
18.
go back to reference Qi X, De Stefano V, Li H, Dai J, Guo X, et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26:23–9.CrossRef Qi X, De Stefano V, Li H, Dai J, Guo X, et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26:23–9.CrossRef
19.
go back to reference Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2019;113:86–91.CrossRef Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2019;113:86–91.CrossRef
20.
go back to reference Kumar S, Kamath PS. Acute superior mesenteric venous thrombosis: one disease or two? Am J Gastroenterol. 2003;98:1299–304.CrossRef Kumar S, Kamath PS. Acute superior mesenteric venous thrombosis: one disease or two? Am J Gastroenterol. 2003;98:1299–304.CrossRef
21.
go back to reference Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis. JAMA Intern Med. 2015;175:1474–80.CrossRef Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis. JAMA Intern Med. 2015;175:1474–80.CrossRef
22.
go back to reference Gell DA. Structure and function of haemoglobins. Blood Cells Mol Dis. 2018;70:13–42.CrossRef Gell DA. Structure and function of haemoglobins. Blood Cells Mol Dis. 2018;70:13–42.CrossRef
23.
go back to reference Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003;111:235–8.CrossRef Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003;111:235–8.CrossRef
24.
go back to reference Mehta G, Augoustaki A, Kouroumalis EA, Samonakis DN. Inflammation and portal hypertension - the undiscovered country. J Hepatol. 2014;61:155–63.CrossRef Mehta G, Augoustaki A, Kouroumalis EA, Samonakis DN. Inflammation and portal hypertension - the undiscovered country. J Hepatol. 2014;61:155–63.CrossRef
25.
go back to reference Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood. 2020;135:1788–810.CrossRef Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood. 2020;135:1788–810.CrossRef
26.
go back to reference Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156:1582–99.CrossRef Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156:1582–99.CrossRef
27.
go back to reference Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy. 2002;34:535–8.CrossRef Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy. 2002;34:535–8.CrossRef
28.
go back to reference Wang SF, Huang YT, Huang CH, et al. Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign. Ann Transl Med. 2020;8:1223.CrossRef Wang SF, Huang YT, Huang CH, et al. Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign. Ann Transl Med. 2020;8:1223.CrossRef
29.
go back to reference McCormick PA, Jenkins SA, McIntyre N, et al. Why portal hypertensive varices bleed and bleed: a hypothesis. Gut. 1995;36:100–3.CrossRef McCormick PA, Jenkins SA, McIntyre N, et al. Why portal hypertensive varices bleed and bleed: a hypothesis. Gut. 1995;36:100–3.CrossRef
30.
go back to reference Satapathy SK, Sanyal AJ. Nonendoscopic management strategies for acute esophagogastric variceal bleeding. Gastroenterol Clin North Am. 2014;43:819–33.CrossRef Satapathy SK, Sanyal AJ. Nonendoscopic management strategies for acute esophagogastric variceal bleeding. Gastroenterol Clin North Am. 2014;43:819–33.CrossRef
31.
go back to reference John BV, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12:952–8.CrossRef John BV, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12:952–8.CrossRef
32.
go back to reference Spaander MC, Hoekstra J, Hansen BE, Van Buuren HR, Leebeek FW, Janssen HL. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11:452–9.CrossRef Spaander MC, Hoekstra J, Hansen BE, Van Buuren HR, Leebeek FW, Janssen HL. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11:452–9.CrossRef
Metadata
Title
Development and external validation of prognostic scoring models for portal vein thrombosis: a multicenter retrospective study
Authors
Xuan Zhong
Shan Li
Jiali Hu
Jinlai Lu
Wei Wang
Miao Hu
Qinjuan Sun
Shuo Zhang
Xiaoqing Yang
Changqing Yang
Lan Zhong
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2023
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-023-00455-w

Other articles of this Issue 1/2023

Thrombosis Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine